Determination of antibiotic effect in an in vitro pharmacodynamic model: Comparison with an established animal model of infection

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 11, 2002, Pages 3574-3579

  Bonapace, Charles R ^a   Friedrich, Lawrence V ^a   Bosso, John A ^a   White, Roger L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TICARCILLIN;

ANIMAL CELL; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; IN VITRO STUDY; INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTI-BACTERIAL AGENTS; BACILLUS SUBTILIS; BACTERIAL INFECTIONS; COLONY COUNT, MICROBIAL; LINEAR MODELS; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; NEUTROPENIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TIME FACTORS;

EID: 0036840407     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.11.3574-3579.2002     Document Type: Article

References (22)

1. Blaser, J., and S. H. Zinner. 1987. In vitro models for the study of antibiotic activities. Prog. Drug Res. 31:349-381.
2. Blaser, J., H. L. Rieder, and R. Lüthy. 1991. Interface-area-to-volume ratio of interstitial fluid in humans determined by pharmacokinetic analysis of netilmicin in small and large skin blisters. Antimicrob. Agents Chemother. 35:837-839.
3. Craig, W. A., and S. C. Ebert. 1992. Continuous infusion of β-lactam antibiotics. Antimicrob. Agents Chemother. 36:2577-2583.
4. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
5. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
6. Gerber, A. U., P. Vastola, J. Brandel, and W. A. Craig. 1982. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J. Infect. Dis. 146:691-697.
7. Gerber, A. U., and C. Feller-Segessenmann. 1985. In-vivo assessment of in-vitro killing patterns of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 15(Suppl. A):201-206.
8. Gilbert, D. N. 1991. Once-daily aminoglycoside therapy. Antimicrob. Agents Chemother. 35:399-405.
9. Grasso, S. 1985. Historical review of in-vitro models. J. Antimicrob. Chemother. 15(Suppl. A):99-102.
10. Jaffe, H. W., A. L. Schroeter, G. H. Reynolds, A. A. Zaidi, J. E. Martin, Jr., and J. D. Thayer. 1979. Pharmacokinetic determinants of penicillin cure of gonococcal urethritis. Antimicrob. Agents Chemother. 15:587-591.
11. Leggett, J. E., B. Fantin, S. Ebert, K. Totsuka, B. Vogelman, W. Calame, H. Mattie, and W. A. Craig. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159:281-292.
12. Leggett, J. E., S. Ebert, B. Fantin, and W. A. Craig. 1991. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand. J. Infect. Dis. 74:179-184.
13. Munckhof, W. J., M. L. Grayson, and J. D. Turnidge. 1996. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J. Antimicrob. Chemother. 37:645-663.
14. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS document M7-A4, vol. 13, no. 2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. Nicolau, D. P., C. D. Freeman, P. P. Belliveau, C. H. Nightingale, J. W. Ross, and R. Quintiliani. 1995. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother. 39:650-655.
16. Peloquin, C. A., T. J. Cumbo, D. E. Nix, M. F. Sands, and J. J. Schentag. 1989. Intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: impact of plasma concentrations, organism MIC, and clinical condition on bacterial eradication. Arch. Intern. Med. 149:2269-2273.
17. Schentag, J. J., R. P. Reitberg, and T. J. Cumbo. 1984. Cefmenoxime efficacy, safety, and pharmacokinetics in critical care patients with nosocomial pneumonia. Am. J. Med. 77(Suppl. 6A):34-42.
18. Van Etta, L. L., L. R. Peterson, C. E. Fasching, and D. N. Gerding. 1982. Effect of the ratio of surface area to volume on the penetration of antibiotics into extravascular spaces in an in vitro model. J. Infect. Dis. 146:423-428.
19. Van Etta, L. L., C. E. Fasching, L. R. Peterson, and D. N. Gerding. 1983. Comparison study of the kinetics of ceftizoxime penetration into extravascular spaces with known surface area/volume ratio in vitro and in vivo in rabbits. Antimicrob. Agents Chemother. 23:49-53.
20. Vogelman, B., and W. A. Craig. 1996. Kinetics of antimicrobial activity. J. Pediatr. 108:835-840.
21. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
22. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.